Huadong Medicine Company Limited (HMC) has acquired Sinclair Pharma Limited, a global aesthetics company headquartered in London, UK, in a deal worth approximately $222 million. HMC is a well-known Chinese pharmaceutical listed company that has established a leading aesthetics business in China and is committed to establishing an aesthetics platform in the United States and other markets.
Sinclair will operate as a stand-alone company under the ownership of HMC. The Sinclair management team will remain in place, with Chris Spooner continuing to serve as Chief Executive Officer.
“This is a significant and exciting opportunity for Sinclair Pharma, positioning us to expand our global operation that aims to be one of the leaders in aesthetics. We continue our commitment to be partners to physicians and to enriching our portfolio with unique, innovative aesthetics products and procedures,” said Mr. Spooner. “HMC has proven experience and the goal of becoming a major global player in the aesthetic market. Its decision to acquire Sinclair to achieve that goal is a testament to our experienced team and our diverse portfolio of effective, high-quality aesthetic products.”
With resources provided by HMC, Sinclair says it plans to grow its US pipeline of longer-duration, minimally-invasive treatments that lead to natural looking results and exceptional patient satisfaction. In the US, Sinclair currently offers Silhouette InstaLift®, an FDA-cleared minimally invasive treatment for repositioning mid-face tissue, which gradually restores facial volume for long-lasting results. Sinclair also plans to continue to build partnerships with US aesthetic physicians and organizations to establish ongoing medical education and training, and to generate additional clinical data, ultimately leading to improved patient outcomes.
“Sinclair’s unique profile and portfolio of proven aesthetic treatments available in key markets around the world, including the United States, Brazil, Korea and Western Europe, gives HMC an ideal opportunity to enter those aesthetic markets,” said Mr. Liang Lv, the CEO of HMC. “With regulatory approval in China we also will be able to offer Sinclair’s pipeline of unique and clinically important products to healthcare consumers in our exciting home market, where we have been marketing high quality specialty drugs for almost 30 years.”